Literature DB >> 16840832

Growth hormone status in morbidly obese subjects and correlation with body composition.

S Savastano1, C Di Somma, A Belfiore, B Guida, F Orio, F Rota, M C Savanelli, T Cascella, A Mentone, L Angrisani, G Lombardi, A Colao.   

Abstract

Morbidly obese subjects are characterized by multiple endocrine abnormalities and these are paralleled by unfavorable changes in body composition. In obese individuals, either 24-h spontaneous or stimulated GH secretion is impaired without an organic pituitary disease and the severity of the secretory defect is proportional to the degree of obesity. The GHRH+arginine (GHRH+ARG) test is likely to be the overall test of choice in clinical practice to differentiate GH deficiency (GHD) patients. Similarly to other provocative tests, GHRH+ARG is influenced by obesity per se. Therefore, a new cut-off limit of peak GH response of 4.2 microg/l in obese subjects has been recently assumed. The aim of the present study was to investigate the reciprocal influence between decreased GH secretion and body composition in a group of 110 morbidly obese subjects, using the new cut-off limit of peak GH response to GHRH+ARG test for these subjects. In our study, GHD was identified in 27.3% of the obese subjects, without gender difference. In GDH obese subjects body mass index (BMI), waist circumference, waist-to-hip ratio (WHR), fat mass (FM), and resistance (R) were higher while reactance (Xc), phase angle, body cell mass (BCM), IGF-I, or IGF-I z-scores were lower than in normal responders (p<0.001). In all obese subjects, GH peak levels showed a negative correlation with age, BMI, waist circumference and FM, and a positive correlation with IGF-I. In the stepwise multiple linear regression, waist circumference and FM were the major determinants of GH peak levels and IGF-I. In conclusion, using the new cut-off limit of peak GH response to GHRH+ARG test for obese subjects, about 1/3 morbidly obese subjects were GHD. GHD subjects showed a significantly different body composition compared with normal responders, and the secretory defect was correlated to different anthropometric variables with waist circumference and FM as the major determinants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840832     DOI: 10.1007/BF03344144

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

1.  Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests.

Authors:  Xiao-Dan Qu; Irene T Gaw Gonzalo; Mohammed Y Al Sayed; Pejman Cohan; Peter D Christenson; Ronald S Swerdloff; Daniel F Kelly; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.

Authors:  G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 3.  Variability in growth hormone stimulation tests.

Authors:  S Fisker; J O Jørgensen; J S Christiansen
Journal:  Growth Horm IGF Res       Date:  1998-02       Impact factor: 2.372

Review 4.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

5.  Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire.

Authors:  F B Hu; E Rimm; S A Smith-Warner; D Feskanich; M J Stampfer; A Ascherio; L Sampson; W C Willett
Journal:  Am J Clin Nutr       Date:  1999-02       Impact factor: 7.045

Review 6.  Gender differences in secretory activity of the human somatotropic (growth hormone) axis.

Authors:  J D Veldhuis
Journal:  Eur J Endocrinol       Date:  1996-03       Impact factor: 6.664

7.  The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.

Authors:  A Colao; G Cerbone; R Pivonello; G Aimaretti; S Loche; C Di Somma; A Faggiano; G Corneli; E Ghigo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

Review 8.  Visceral obesity and the role of the somatotropic axis in the development of metabolic complications.

Authors:  C Franco; B A Bengtsson; G Johannsson
Journal:  Growth Horm IGF Res       Date:  2001-06       Impact factor: 2.372

9.  Interaction of free fatty acids and arginine on growth hormone secretion in man.

Authors:  M Maccario; M Procopio; S Loche; M Cappa; V Martina; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1994-02       Impact factor: 8.694

Review 10.  Hormones and obesity.

Authors:  P G Kopelman
Journal:  Baillieres Clin Endocrinol Metab       Date:  1994-07
View more
  17 in total

1.  Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding.

Authors:  Giulia Galli; Aldo Pinchera; Paolo Piaggi; Paola Fierabracci; Monica Giannetti; Giorgia Querci; Giovanni Scartabelli; Luca Manetti; Giovanni Ceccarini; Silvia Martinelli; Claudio Di Salvo; Marco Anselmino; Fausto Bogazzi; Alberto Landi; Paolo Vitti; Margherita Maffei; Ferruccio Santini
Journal:  Obes Surg       Date:  2012-08       Impact factor: 4.129

2.  Beyond waist circumference in an adult male population of Southern Italy: Is there any role for subscapular skinfold thickness in the relationship between insulin-like growth factor-I system and metabolic parameters?

Authors:  S Savastano; A Barbato; C Di Somma; B Guida; G Pizza; L Barrea; S Avallone; M Schiano di Cola; P Strazzullo; A Colao
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

Review 3.  Bioelectrical impedance vector analysis (BIVA) for the assessment of two-compartment body composition.

Authors:  R Buffa; E Mereu; O Comandini; M E Ibanez; E Marini
Journal:  Eur J Clin Nutr       Date:  2014-08-20       Impact factor: 4.016

4.  Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype.

Authors:  Xuezheng Sun; Hazel B Nichols; Whitney Robinson; Mark E Sherman; Andrew F Olshan; Melissa A Troester
Journal:  Cancer Causes Control       Date:  2015-10-01       Impact factor: 2.506

5.  Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women.

Authors:  C Di Somma; A Rivellese; G Pizza; L Patti; A De Rosa; P Cipriano; V Nedi; A Rossi; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2011-02       Impact factor: 4.256

6.  Association of beta2-adrenergic receptor and insulin receptor substrate-1 polymorphisms with obesity in a Northern Indian population.

Authors:  Neena Srivastava; B R Achyut; Jai Prakash; C G Agarwal; D C Pant; Balraj Mittal
Journal:  Indian J Hum Genet       Date:  2008-05

Review 7.  Endocrine changes (beyond diabetes) after bariatric surgery in adult life.

Authors:  S Savastano; C Di Somma; R Pivonello; G Tarantino; F Orio; V Nedi; A Colao
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

8.  Relationship between growth hormone/insulin-like growth factor-1 axis integrity and voluntary weight loss after gastric banding surgery for severe obesity.

Authors:  Silvia Savastano; Luigi Angrisani; Carolina Di Somma; Francesca Rota; Maria Cristina Savanelli; Teresa Cascella; Francesco Orio; Gaetano Lombardi; Annamaria Colao
Journal:  Obes Surg       Date:  2009-07-28       Impact factor: 4.129

9.  Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls.

Authors:  Madhusmita Misra; Miriam A Bredella; Patrika Tsai; Nara Mendes; Karen K Miller; Anne Klibanski
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-10       Impact factor: 4.310

10.  Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency.

Authors:  C Di Somma; R Pivonello; G Pizza; A De Rosa; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2009-09-30       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.